WO2023012691 - TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS
National phase entry is expected:
Publication Number
WO/2023/012691
Publication Date
09.02.2023
International Application No.
PCT/IB2022/057210
International Filing Date
03.08.2022
Title **
[English]
TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS
[French]
ADMINISTRATION POSOLOGIQUE TRANSDERMIQUE D'AGENTS PHARMACEUTIQUES
Applicants **
PIKE THERAPEUTICS INC.
250 Howe Street
20th Floor
Vancouver, British Columbia V6C 3R8, CA
Inventors
PLAKOGIANNIS, Fotios M.
157-14 Cryders Lane
Whitestone, New York 11357, US
MODI, Nisarg
32 Logan Avenue
1st Floor
Jersey City, New Jersey 07306, US
Priority Data
63/229,015
03.08.2021
US
63/324,288
28.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3411 | |
| EPO | Filing, Examination | 33488 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 606 | |
| USA | Filing, Examination | 13160 |
Total: 51253 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to the transdermal administration of pharmaceutical agents, such as CBD, THC, psilocybin, psilocin, lysergic acid diethylamine (LSD), and/or ibogaine, and derivatives of these compounds, for the treatment and/or prevention and/or control of severe depression (treatment resistant), major depressive disorder, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, opioid addiction, anxiety (stress), adult ADHD, cluster headaches, and cancer related or other end-of-life psychological distress.[French]
La présente invention concerne l'administration transdermique d'agents pharmaceutiques, tels que le CBD, le THC, la psilocybine, la psilocine, la diéthylamine de l'acide lysergique (LSD) et/ou l'ibogaïne, ainsi que des dérivés de ces composés, pour le traitement et/ou la prévention et/ou la régulation de la dépression sévère (résistant au traitement), du trouble dépressif majeur, du trouble obsessionnel compulsif, du sevrage du tabac, de la dépendance à l'alcool, de la dépendance à la cocaïne, de la dépendance aux opioïdes, de l'anxiété (stress), du TDAH de l'adulte, de l'algie vasculaire de la face et d'une autre détresse psychologique liée au cancer ou à la fin de vie.